121 results on '"Fang W"'
Search Results
2. 320MO Envonalkib vs crizotinib in treatment-naïve advanced ALK-positive NSCLC: A randomized, multicenter, phase III trial
3. 332P A phase II, open-label, single-center study of QL1706 plus platinum doublet chemotherapy with bevacizumab as first-line treatment in patients with advanced NSCLC: Data from EGFR mutant cohort
4. 117P Immunoprofile of adenosquamous carcinoma in gastric cancer
5. 373P Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2
6. 325P A phase II, open-label, single-center study of QL1706 plus platinum doublet chemotherapy with or without bevacizumab as first-line treatment in patients with advanced NSCLC: Data from EGFR wild-type cohort
7. 1446P Efficacy and safety of cadonilimab combined albumin-paclitaxel, cisplatin and fluorouracil (APF) in neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): Results from the CAPITAL trial
8. 861P Neo-TIME trial: Neoadjuvant tislelizumab combined with albumin-paclitaxel, cisplatin, and fluorouracil(APF) in patients with locally advanced oral squamous cell carcinoma (LA-OSCC)
9. 605O YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study
10. P-19 Subgroup analysis of the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)
11. SO-17 A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer
12. P-25 Tislelizumab monotherapy for patients with previously treated advanced hepatocellular carcinoma (HCC): RATIONALE-208 Chinese subpopulation
13. 81MO Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated results
14. 121O RATIONALE 309: A randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine + cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)
15. 936P Effects of tislelizumab (TIS) monotherapy on health-related quality of life in patients with previously treated unresectable hepatocellular carcinoma (HCC)
16. 1466P Napabucasin + nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study
17. 1771P Identification and validation of tissue or ctDNA PTPRD phosphatase domains deleterious mutations as prognostic and predictive biomarkers for ICIs in non-squamous NSCLC
18. 1329P A single-arm, open-label, multi-center, phase I study of HA121-28 in patients with advanced solid tumors
19. 1293P KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with platinum doublet chemotherapy as first-line (1L) treatment in patients with advanced NSCLC harboring resistant oncogenic driver alterations
20. O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma
21. 2375P Neoadjuvant sintilimab combined with gemcitabine and cisplatin (GP) for muscle-invasive bladder cancer (MIBC) patients followed by selective bladder sparing surgery
22. 2186P KN046 in patients with thymic carcinoma: A prospective, single-arm, multi-centre, phase II study
23. 1504TiP HARMONi: Randomized, double-blind, multi-center, phase III clinical study of ivonescimab or placebo combined with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have progression following EGFR-TKI treatment
24. 1449P The preliminary data from a single-arm, open-label, multicenter phase II clinical trial: KN046 combined with axitinib as first-line (1L) treatment for NSCLC
25. 1247P A detection model for EGFR mutations in lung adenocarcinoma patients based on volatile organic compounds
26. 1060P Balance of CD36+ and CD16+ monocytes controls TLR-mediated cytokine release syndrome and MHC-dependent antitumor responses in EpCAM CAR T cell therapy for gastrointestinal cancers
27. 948P Phase (Ph) I/II study of sitravatinib (Sitra) alone or with tislelizumab (TIS) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/GEJC)
28. 556MO A phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab in patients with MSS/pMMR metastatic colorectal cancer
29. Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma
30. 109P Efficacy and safety of biweekly or triweekly XELOX regimen for adjuvant chemotherapy of colorectal cancer
31. 1224P Potential modifiable risk factors and lung cancer: A Mendelian randomization analysis
32. 985P A phase II study of camrelizumab for advanced hepatocellular carcinoma: Two-year outcomes and continued treatment beyond RECIST-defined progression
33. 737MO EpCAM-targeted CAR-T cell therapy in patients with advanced colorectal and gastric cancers
34. PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in NSCLC
35. Combined model of frameshift mutations and TMB in predicting response to immunotherapy in NSCLC
36. Mendelian randomization study showed no causality between metformin use and lung cancer risk
37. Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer
38. Comprehensive genomic profiling of thymic carcinoma in a sample Chinese population
39. Simultaneous resection of pancreatic cancer and liver oligometastases after induction chemotherapy in stage IV patients: An open-label prospective randomized multicenter phase III trial (CSPAC-1)
40. A Mendelian randomization study of the effects of Crohn’s disease on lung cancer
41. Nomogram for patients with stage I small cell lung cancer: A competing risk analysis
42. Education and lung cancer: A Mendelian randomisation study
43. Asthma and risk of lung cancer: A mendelian randomization study
44. Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer (mCRC): A preplanned analysis of the phase III AXEPT trial
45. Whether pericarcinomatous tissue of non-small cell lung cancer can serve as genetic background filter in next-generation sequencing analysis
46. Dynamic monitoring of KRAS, NRAS, BRAF and PIK3CA mutations in circulating cell-free DNA for metastatic colorectal cancer patients treated with cetuximab
47. Genomic profile and T cell receptor repertoire of lung adenosquamous carcinomas
48. 397PD KRAS mutation-induced upregulation of PD-L1 mediates immune escape in lung adenocarcinoma
49. 271P Target therapy treatment patterns on advanced gastrointestinal stromal tumor (GIST) patients: a nation-wide cohort study in Taiwan
50. 320O - PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in NSCLC
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.